Efinaconazole, sold under the brand name Jublia among others, is a triazole antifungal medication. It is approved for use in the United States, Canada, and Japan as a 10% topical solution for the treatment of onychomycosis (fungal infection of the nail).
It is available as a generic medication.
Medical uses
Efinaconazole is an
azole antifungal indicated in the US for the topical treatment of
onychomycosis of the
due to
Trichophyton rubrum and
Trichophyton mentagrophytes.
Efficacy
In two
17.8% (trial 1) and 15.2% (trial 2) of participants using efinaconazole were completely cured (0% clinical involvement of the target toenail, plus negative
KOH test and negative culture), compared with 3.3% (trial 1) and 5.5% (trial 2) of participants using a
placebo.
The "complete cure or almost complete cure" rate (≤5% affected target toenail area involved, and negative KOH and culture) for efinaconazole was 26.4% (trial 1) and 23.4% (trial 2) (compared with 7.0% (trial 1) and 7.5% (trial 2)).
History
In 2014, the U.S. Food and Drug Administration (FDA) approved the New Drug Application (NDA).
According to Valeant Pharmaceuticals International Inc CEO J. Michael Pearson they acquired Jublia through their purchase of Dow Pharmaceutical Sciences in 2008.
In 2020, the FDA approved a supplemental New Drug Application for efinaconazole topical solution, 10%, which extended the age range included in the product's label to children six years of age and older; it was first approved in 2014, in people aged 18 years of age and older.
Society and culture
Economics
In 2015, the cost of treatment with efinaconazole in the United States was said to be per nail.
In 2019, a study by the Canadian Agency for Drugs and Technologies in Health found the cost for a 48-week course to be $178 for a big toe, and $89 for an other toe.
External links
